APA (7th ed.) Citation

Degasperi, E., Anolli, M. P., Jachs, M., Reiberger, T., De Ledinghen, V., Metivier, S., . . . Lampertico, P. (2025). Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis. Journal of hepatology, 82(6), . https://doi.org/10.1016/j.jhep.2024.12.044

Chicago Style (17th ed.) Citation

Degasperi, Elisabetta, et al. "Real-world Effectiveness and Safety of Bulevirtide Monotherapy for Up to 96 Weeks in Patients with HDV-related Cirrhosis." Journal of Hepatology 82, no. 6 (2025). https://doi.org/10.1016/j.jhep.2024.12.044.

MLA (9th ed.) Citation

Degasperi, Elisabetta, et al. "Real-world Effectiveness and Safety of Bulevirtide Monotherapy for Up to 96 Weeks in Patients with HDV-related Cirrhosis." Journal of Hepatology, vol. 82, no. 6, 2025, https://doi.org/10.1016/j.jhep.2024.12.044.